Article

Study provides insight on long-term outcomes after hyperopic LASIK

Hyperopic LASIK (H-LASIK) has limited predictability and declining efficacy during long-term follow-up, but its safety remains good and patient satisfaction stays high, said Reena Mahendra Dave, MD.

By Cheryl Guttman Krader

Las Vegas-Hyperopic LASIK (H-LASIK) has limited predictability and declining efficacy during long-term follow-up, but its safety remains good and patient satisfaction stays high, said Reena Mahendra Dave, MD.

Dr. Dave, Guy’s and St. Thomas’ Hospital, London, reported findings from an analysis of data collected for 33 eyes of 19 patients evaluated at a mean of 16.5 years after H-LASIK.

The mean age at time of correction was 51.6 years (range 34 to 60 years), mean preoperative spherical equivalent (SEQ) was +3.73 D (range +1.25 to +6.5 D), and minimum follow-up was 15 years, said Dr. Dave at the 2015 meeting of the American Academy of Ophthalmology.

 

The results showed mean hyperopic SEQ increased significantly between 1, 5, and 16.5 years (mean +0.28 versus +0.84 versus +1.74 D); at 16.5 years, only 24% of eyes were ±1.0 D and only 6% were ±0.5 D. Mean SEQ increased similarly over time in eyes with lower versus higher power corrections (< +3.0 versus >+3.5 D).

However, the annual rate of refractive change was greater in the first 5 years than between 5 and 16.5 years, and in an age-based analysis, the hyperopic increase in SEQ was less in older (>53 years) than in younger (<52 years) age patients, although the difference between the two subgroups was not statistically significant.

The increase in hyperopic SEQ also translated into declining efficacy as the efficacy index decreased from 0.98 at 1 year to 0.5 at 16.5 years.

 

Nevertheless, 89% of patients were happy and 75% said they would recommend LASIK to family and friends.

The safety index at 16.5 years was 1.09. Five eyes had undergone cataract surgery, but there were no late complications, including no evidence of ectasia based on topographic analysis, Dr. Dave noted.

The refractive changes between 5 and 16.5 years reflect an expected age-related hyperopic shift, but it was found that keratometry values remained stable over time, which suggests that the hyperopic drift after H-LASIK is probably due to physiological lenticular changes rather than regression at the level of the cornea.

Keeping in mind the development of visually significant cataract and that the hyperopic increase in SEQ was less in the older age patients, it appears that time and advancing age may mask any hyperopic drift, Dr. Dave added.

 

Dr. Dave noted that while H-LASIK was first performed about 20 years ago, the longest term studies only include follow-up to 5 years.

The 19 patients included in the study were treated between 1998 and 1999 and returned after recall for a complete ophthalmic examination. They were part of a total cohort of 52 patients who had undergone H-LASIK. There were no significant differences between the 19 evaluated patients and those who did not return with respect to mean age, preoperative spherical equivalent preoperative cylinder, attempted correction, or achieved refractive correction at 12 months.

 

 

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.